The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Collection of baseline data from the first 580 patients

Abstract

This paper provides an overview of the baseline data collected in the nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project. The paper presents descriptive data from the first 580 patients enrolled in the DD2. The DD2 database will contain detailed interview data, clinical examination data, and urine and blood samples from up to 10,000 patients newly diagnosed with type 2 diabetes each year, collected from general practitioners and hospital outpatient clinics in all of Denmark. Of the first DD2 patients enrolled, blood and urine samples have been obtained from 97%. The median age of the first 580 patients was 59 years and 322 (56%) were men. Median weight gain from age 20 to maximum lifetime weight was 29 kg for men and 31 kg for women, and 364 patients (63%) did not currently participate in regular sports activities. Two hundred and ninety two patients (50%) had a known family history of diabetes. Two hundred fifty (43%) of the 580 DD2 patients have also been enrolled in the Danish Diabetes Database for Adults from which additional clinical data can be obtained. Among these 250 patients (154 of whom were men, 96 women), 75 (49%) men were currently obese, and 63 (41%) were overweight, whereas 62 (65%) women were obese, and another 21 (22%) were overweight. Twenty-nine patients (12%) received insulin, 164 patients (66%) received oral antidiabetics only, and 57 (23%) received no antidiabetic treatment. Glycemic regulation was modest (the glycosylated hemoglobin A of 46% was ≥7.5%). Two thirds of the patients received antihypertensive and hypolipidemic treatment. Self-reported daily tobacco smoking (23%) and alcohol overuse (6%) seemed comparable to occurrence in the general Danish population. One quarter of the patients with newly diagnosed diabetes had a history of hospital-diagnosed comorbidity at baseline as included in the Charlson comorbidity index, in particular prior myocardial infarction (5%), cerebrovascular disease (5%), peripheral vascular disease (4%), chronic pulmonary disease (6%), and previous solid cancer (6%). In the future, the DD2 database represents a valuable source for outcome studies in type 2 diabetes.

Lifestyle Factors Associated with Type 2 Diabetes and Use of Different Glucose-Lowering Drugs: Cross-Sectional Study

“…Metformin is the recommended first-line drug for Type 2 DM patients with obesity [26], and many of our metformin users had a short history of diabetes with relatively little time for effective lifestyle changes. Our results are similar to the prevalence of obesity (54%) observed in metformin users in the United Kingdom Prospective Diabetes Study (UKPDS) [27], and slightly lower than the current obesity prevalence of about 60% in newly diagnosed Type 2 DM patients enrolled in the Danish DD2 study [22] of whom 59% are started with metformin monotherapy within the first year [28]. A large study based on the Swedish National Diabetes Register involving more than 51,000 Type 2 DM patients reported similar observation, with users of metformin-containing therapies having shortest duration of diabetes and higher mean BMI (30 to 32 kg/m 2 ) than users of other oral glucose-lowering drugs or insulin (27 to 28 kg/m 2 ) [29].…”

Prescribing practices and clinical predictors of glucose‐lowering therapy within the first year in people with newly diagnosed Type 2 diabetes

“…Additionally, the prescribing behaviour of GPs compared with specialists may influence the findings . Because the DD2 cohort was in its early phase of enrolment in 2010‐2013, recruitment from hospital clinics was ahead of that from GPs and our results may refer to more severe cases of Type 2 diabetes mellitus than the average in Denmark .…”

National trends in incidence and outcomes in lower extremity amputations in people with and without diabetes in Spain, 2001–2012

“…The index is subsequently categorized into three levels: no disease; one disease; and two or more diseases. To calculate the CCI we used 16 disease categories, excluding diabetes, as described by Thomsen et al [14].…”